Board of Directors


Kim Bjørnstrup
Chairman, independent

Mr. Bjørnstrup has been Chairman of the Board of Veloxis since April 2011. He has more than 20 years of working experience in the pharmaceutical industry. During the past 18 years, he has held various executive positions in the management team of the Octapharma Group and served 8 years as Vice Chairman. Prior to this, he has worked with Coloplast A/S and H. Lundbeck A/S.

Special competencies, important for his capacity as a board member, comprise his extensive international biotechnology industry experience and network together with his extensive business development experience.

As of 1. August 2013 Kim Bjørrnstrup has been appointed CEO of BPL Holdings Ltd. BPL Holding is an organization focused on manufacturing and selling Lifesaving drugs based on human plasma. The group employs 1800 people and is headquartered in Elstree outside London. Kim Bjørnstrup is trained as a lawyer and holds a Master of Law from Copenhagen University.



Dr. Thomas Dyrberg
Deputy Chairman, independent

Dr. Dyrberg has been a Board Member of Veloxis since September 2003.

Special competencies, important for his capacity as a board member of Veloxis, comprise his extensive life-science experience and funding of biotechnological companies.

Dr. Dyrberg, Senior Partner, has served at Novo Ventures, Novo A/S, a Danish firm that provides capital for life science companies, since December 2000.

Prior to joining Novo A/S, he served in various positions at Novo Nordisk A/S, a health care company specializing in the treatment of diabetes. Prior to that, he held research positions at the Hagedorn Research Institute, Gentofte, Denmark, and the Scripps Research Institute, La Jolla, California, US.

Dr. Dyrberg received both an MD and a DMSc degree from the University of Copenhagen.

Dr. Dyrberg is board member of Ophthotech Corp, Panoptica Inc, Theia Inc and Delenex Therapeutics AG.

Dr. Dyrberg is an independent board member.

 



Mette Kirstine Agger
Board member, independent

Ms. Agger has been a Board Member of Veloxis since April 2010. Ms. Agger is Managing Partner of Lundbeckfond Ventures, a company fully owned by the Lundbeck Foundation, which she joined on 1 September 2009.

Ms. Agger's special competencies, which are important for her capacity as a board member, are her extensive biotechnology industry experience and network together with her extensive business development experience and knowledge of intellectual properties within the pharmaceutical sector.

Prior to this, Ms. Agger was CEO of 7TM Pharma A/S, which she cofounded in late 2000, and from 1996 to 2000 she was part of the management team at NeuroSearch A/S, responsible for business development and licensing.

Ms. Agger has a Master of Science in Biology from Copenhagen University and an MBA from the Henley Business School, UK.

Ms. Agger is a board member of Klifo A/S, PsiOxus Therapeutics Ltd, Cydan LLC, scPharmaceuticals LLC, Thesan Pharamceuticals Inc and Vtesse Pharma.

Ms. Agger is an independent board member.

 



Anders Götzsche
Board member, independent

Mr. Götzsche has been a Board Member of Veloxis since April 2008. Mr. Götzsche is Executive Vice President and Chief Financial Officer at H. Lundbeck A/S. He joined Lundbeck on 1 September 2007.

Special competencies, important for his capacity as a board member of Veloxis, comprise his experience from international and financial management.

After finishing his education in 1991, he joined PricewaterhouseCoopers in Denmark. From 1998 through 2001, Mr. Götzsche was a Sales Manager with the SAS Institute Inc. He became Director of Group Accounting and Reporting for Group 4 Falck A/S. Before joining Lundbeck, Mr. Götzsche held the post of Chief Financial Officer for the Berlingske Officin A/S from 2005.

Mr. Götzsche holds a Master of Science in Accounting from the University of Southern Denmark and became a state authorized public accountant in 1997.

Mr. Götzsche is the Chairman of Rosborg Møbler A/S.

Mr. Götzsche is an independent board member.